Histological assessment of non-alcoholic fatty liver disease (Q36634377)

15 August 2017

1 reference

title

Histological assessment of non-alcoholic fatty liver disease (English)

1 reference

non-alcoholic fatty liver

15 August 2017

0 references

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

Hübscher SG

1

1 reference

15 August 2017

1 November 2006

1 reference

15 August 2017

1 reference

15 August 2017

49

1 reference

15 August 2017

450-465

1 reference

15 August 2017

5

1 reference

Cytokines and the pathogenesis of non-alcoholic steatohepatitis

15 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

The metabolic syndrome--a new worldwide definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Recent concepts in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Long term prognosis of fatty liver: risk of chronic liver disease and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Non-alcoholic steatohepatitis: from cell biology to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Should a liver biopsy be done in patients with subclinical chronically elevated transaminases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Role of polymerase chain reaction and liver biopsy in the evaluation of patients with asymptomatic transaminitis: implications in diagnostic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Clinical significance of elevated alanine aminotransferase in blood donors: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Silent non-alcoholic fatty liver disease-a clinical-histological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

21 January 2018

Mallory bodies revisited

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Review article: steatosis, the metabolic syndrome and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Insulin resistance: a metabolic pathway to chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Etiopathogenesis of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Nonalcoholic fatty liver disease: an agenda for clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

NASH: a mitochondrial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Adiponectin and its receptors in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Review article: the pathogenesis of fibrosis in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Impact of steatosis on progression of fibrosis in patients with mild hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Clinical and pathological features of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Ubiquitin as a marker of cell injury in nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Apoptosis: a mechanism of acute and chronic liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Mitochondrial abnormalities in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Preneoplastic lesions in human hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Nonalcoholic steatohepatitis: definition and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Pathologic features associated with fibrosis in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Hepatic iron and nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Steatosis: co-factor in other liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Steatohepatitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Fatty liver disease in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Nonalcoholic fatty liver disease in the pediatric population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Non-alcoholic steatohepatitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Idiopathic steatohepatitis in childhood: a multicenter retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Nonalcoholic Steatohepatitis in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Histopathology of pediatric nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

The utility of radiological imaging in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Diagnosis of fatty liver disease: is biopsy necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Pathology of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

The natural history of nonalcoholic fatty liver: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Obesity and alcoholic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Nonalcoholic steatohepatitis-related cirrhosis with subacute liver failure: an autopsy case.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Interaction of non-alcoholic fatty liver disease with other liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Insulin resistance and insulin secretion in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Insulin resistance and steatosis in hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Obesity and non-alcoholic fatty liver disease in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Steatosis affects chronic hepatitis C progression in a genotype specific way

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Chronic hepatitis C and superimposed nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Hepatitis C virus infection and liver steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Contribution of obesity to hepatitis C-related fibrosis progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Steatosis and fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

NASH: a hidden and silent fibroser finally revealed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Liver fibrosis in overweight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Assessment of donor liver steatosis: pathologist or automated software?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Hepatocyte Apoptosis, Expression of Death Receptors, and Activation of NF-κB in the Liver of Nonalcoholic and Alcoholic Steatohepatitis Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

A Clinical–Morphological Study on Cholestatic Presentation of Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02416.X

10.1111/J.1365-2559.2006.02416.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17064291